The Calmer Project
16 juli 2018 uppdaterad av: Liisa Holsti, Children's & Women's Health Centre of British Columbia
Calmer: A Novel Approach for Treating Infant Pain
The purpose of this study is to see if the Calmer is more effective at managing acute pain in preterm infants in the neonatal intensive care than the current standard of care in the unit.
Hypothesis: While receiving treatment with Calmer, infants will show lower behavioral pain scores and lower heart rates, and more stable autonomic regulation as measured by heart rate variability indices, than infants given a soother plus facilitated tucking (standard of care) during routine blood collection.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Detaljerad beskrivning
60 infants will be randomized to either receive the standard of care or the Calmer during a routine blood collection.
Studietyp
Interventionell
Inskrivning (Faktisk)
54
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6H3V4
- BC Children's and Women's Health Centre
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
6 månader till 8 månader (Barn)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Stable infants admitted to the Neonatal Intensive Care Unit at Children's and Women's Health Centre of British Columbia (C&W)
- Preterm infants born at 27 to 36+6 completed weeks gestational age (GA) will be included
- GA is determined on the basis of the first day of the last menstrual period, early gestation ultrasonogram (in most cases) or best estimate based on neonatal examination
- Mothers must speak enough English to provide consent
Exclusion Criteria:
- Infants who have congenital anomalies, active, ongoing infection, or have undergone surgery
- Infants who have received pharmacological analgesics or sedatives within 72 hours of the assessment
- History of maternal abuse of controlled drugs and substances; blood collection that occurs beyond the 35th completed week (35 weeks + 6 days) GA
- Small for GA defined as a birth weight at least 2 standard deviations below mean for GA
- Higher order multiples (e.g. triplets)
- Infants in a cot
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Stödjande vård
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Calmer
This therapeutic platform, called the Calmer interacts with the infant to help reduce stress to help promote better outcomes.
It is being tested to see if it mimics Kangaroo care, maternal skin to skin, to help promote better health outcomes.
Infants would be placed on it prior, during and after bloodwork to see if it elicits a favorable response.
|
This platform, called the Calmer, interacts with the infant to help reduce stress to help promote better outcomes.
Infants can be placed on it for care to mimic Kangaroo Care, maternal skin to skin.
|
|
Placebo-jämförare: Standard Care
Standard of care during bloodwork is receiving a soother and facilitated tucking.
|
Infant would receive the standard of care for bloodwork, provided a soother and facilitated tucking.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Behavioral Indicators of Infant Pain (BIIP) Score
Tidsram: During the assessment period in the study, estimated to occur around one hour.
|
The Behavioral Indicators of Infant Pain (BIIP) is a reliable and valid scale for assessing acute procedural pain in preterm infants.
|
During the assessment period in the study, estimated to occur around one hour.
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Secondary Outcome Measures: Heart Rate
Tidsram: During and after the assessment period in the study, estimated to be 6 hours.
|
Heart rate will be recorded during the assessment period, one hour, to denote changes.
Additionally, the heart rate will be recorded after the assessment period, for approximately 5 hours.
|
During and after the assessment period in the study, estimated to be 6 hours.
|
|
Secondary Outcome Measures: Heart Rate Variability
Tidsram: During and after assessment period in the study, estimated to be 6 hours.
|
Heart rate variability during the assessment period will be recorded, monitored and reviewed for changes, estimated to occur over the course of an hour.
Additionally, the heart rate variability will be recorded after the assessment period, for approximately 5 hours.
|
During and after assessment period in the study, estimated to be 6 hours.
|
|
Secondary Outcome Measures: NIRS
Tidsram: During the assessment period in the study, estimated to occur over less than an hour.
|
Brain blood oxy- and de-oxyhemoglobin, TSI, total hemoglobin, using near infra-red spectroscopy.
During the assessment period in the study, estimated to occur around one hour.
|
During the assessment period in the study, estimated to occur over less than an hour.
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Utredare
- Huvudutredare: Liisa Holsti, PhD, Developmental Neurosciences and Child Health, Child and Family Research Institute and Dept. of Occupational Science and Occupational Therapy, UBC
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 oktober 2014
Primärt slutförande (Faktisk)
1 maj 2018
Avslutad studie (Faktisk)
1 maj 2018
Studieregistreringsdatum
Först inskickad
9 september 2011
Först inskickad som uppfyllde QC-kriterierna
13 september 2011
Första postat (Uppskatta)
14 september 2011
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
17 juli 2018
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
16 juli 2018
Senast verifierad
1 juli 2018
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CALMERP
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .